2021
Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.
Yee ME, Lai KW, Bakshi N, Grossman JK, Jaggi P, Mallis A, Wang YF, Jerris RC, Lane PA, Yildirim I. Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019. Pediatrics 2021, 149 PMID: 34913059, PMCID: PMC8959248, DOI: 10.1542/peds.2021-051892.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBloodstream infectionsBlood culturesSickle cell anemia genotypesRetrospective cohort studyInvasive bacterial infectionsMultivariate logistic regressionConfidence intervalsAverage incidence rateSpectrum of pathogensAntibiotic prophylaxisEligible patientsFunctional aspleniaBSI episodesCohort studyChronic transfusionMedian ageAnnual incidenceOverall incidenceRisk factorsIncidence rateCell diseaseEmpirical treatmentBordetella holmesiiCommon pathogens
2008
PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES
Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, Secmeer G, Yetgin S. PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES. Pediatric Hematology And Oncology 2008, 25: 291-299. PMID: 18484473, DOI: 10.1080/08880010802016847.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmikacinAnti-Bacterial AgentsBacteriaBacterial InfectionsCarbapenemsChildChild, PreschoolDrug Therapy, CombinationEnzyme InhibitorsFemaleHumansLeukemia, Myeloid, AcuteMaleNeutropeniaPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationPrecursor Cell Lymphoblastic Leukemia-LymphomaConceptsFebrile neutropenic episodesDuration of feverPiperacillin/tazobactamCarbapenem monotherapyNeutropenic episodesHematological malignanciesFebrile neutropeniaEmpirical treatmentInitial empirical regimenInfection-related mortalityPediatric hematological malignanciesChildhood hematological malignanciesAcute lymphoblastic leukemiaAcute myeloblastic leukemiaAmikacin combinationEmpirical regimenPTA groupCarbapenem groupLymphoblastic leukemiaTreatment modificationAntimicrobial therapyClinical trialsTreatment successAdditional antibioticsCommon cause